I hate to reply to my own post like someone else we all know, but I thought I'd clarify the point further. Don't forget that the data gathered from the CLIA lab will serve as AMBS's large-scale study to be used when they seek approval from the FDA. That's why the sample sizes in these recent validation studies haven't been larger -- because there will be a time for that during CLIA. At least that's how I understand it. The partner for FDA approval could be the same as CLIA or a different completely company. I always assumed GC would handle these separately, but with time frames pushed back a bit, perhaps it could be the same partner for both steps in the process just for security and a bigger bang right away. I guess we'll just have to wait and see.
I tried fighting the good fight on YMB but it's pointless. I replied to someone ripping GC today by showing him the increase in market cap from 8/13/12 (1 million) to 8/13/13 (17 million) to today (77 million). He subsequently deleted the whole thread so it wouldn't appear anymore. Thank you for starting and maintaining this board.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links